biopharmaceutical

Jan 19, 2017

Astellas ditches UMN Pharma; J&J, Actelion land on a price; Bayer’s pledge; Biogen to fork over $1.25B-plus

Dec 15, 2016

CDC study reveals; Jevtana receives yes; Herantis secures; Immuno-oncology is not cost-effective

Mar 13, 2015

Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis

Newsletter/Whitepaper